leisure time -WSS

leisure time

author：hotspot 2025-09-27 16:11:35 - browse：9987

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： PhRMA sues HHS over Medicare drug price negotiation

focus

WSS

Military medical care influenced by rank and race, new study finds

Inside the fall of star MIT scientist David Sabatini

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Australia's humpback populations rebound raising hopes of marine scientists

entertainment

leisure time

focus

Activists slam private health insurers over coverage restrictions

Meta looks to target Twitter with a rival app called Threads

Hollywood unions extend contract negotiations for actors

Criminal prosecution for violating HIPAA: an emerging threat

In age of alternative facts, a scholarly course on calling out crap

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

BioMarin wins approval for gene therapy to treat hemophilia A

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

BioMarin wins approval for gene therapy to treat hemophilia A

Helping hospitals and community health centers plan for resilience

Wikipedia

Can food be medicine? And other questions about a new push

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Addiction experts warn against a second 'war on drugs'

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Helping hospitals and community health centers plan for resilience

explore

focus

entertainment

focus